Sierra Oncology Inc (SRRA) Stock Price, Forecast & Analysis
NASDAQ:SRRA • US82640U4040
SRRA Key Statistics, Chart & Performance
The current stock price of SRRA is 54.99 null. In the past month the price increased by 0.38%. In the past year, price increased by 178.43%.
SRRA Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to SRRA. When comparing the yearly performance of all stocks, SRRA is one of the better performing stocks in the market, outperforming 99.87% of all stocks.
SRRA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to SRRA. No worries on liquidiy or solvency for SRRA as it has an excellent financial health rating, but there are worries on the profitability.
SRRA Financial Highlights
Over the last trailing twelve months SRRA reported a non-GAAP Earnings per Share(EPS) of -6.77. The EPS decreased by -7.29% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -36.67% | ||
| ROE | N/A | ||
| Debt/Equity | 0.02 |
SRRA Forecast & Estimates
10 analysts have analysed SRRA and the average price target is 56.1 null. This implies a price increase of 2.02% is expected in the next year compared to the current price of 54.99.
SRRA Ownership
SRRA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.45 | 404.235B | ||
| AMGN | AMGEN INC | 16.66 | 204.477B | ||
| GILD | GILEAD SCIENCES INC | 16.94 | 189.501B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.02 | 119.327B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.84 | 83.747B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 50.66 | 43.95B | ||
| INSM | INSMED INC | N/A | 32.227B | ||
| NTRA | NATERA INC | N/A | 29.989B | ||
| BIIB | BIOGEN INC | 12.63 | 28.491B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.31 | 20.499B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About SRRA
Company Profile
Sierra Oncology, Inc. is a clinical stage drug development company of therapeutics for the treatment of cancer. The company is headquartered in Vancouver, British Columbia and currently employs 109 full-time employees. The company went IPO on 2015-07-16. The Company’s lead product candidate, momelotinib, which is a selective and orally bioavailable janus kinase one (JAK1), janus kinase two (JAK2) and activin a receptor type one (ACVR1) inhibitor under investigation for the treatment of myelofibrosis. The firm is also developing a portfolio of deoxyribonucleic acid (DNA) damage response (DDR) assets, consisting of SRA737 and SRA141. SRA737 is a bioavailable small molecule inhibitor of checkpoint kinase 1 (Chk1), which is a key regulator of cell cycle progression and the DDR network. SRA141 is a bioavailable small molecule inhibitor of Cell division cycle 7 kinase (Cdc7).
Company Info
Sierra Oncology Inc
2150 ? 885 West Georgia Street, Suite 110
Vancouver BRITISH COLUMBIA V6C 3E8 CA
CEO: Stephen G. Dilly
Employees: 109
Phone: 16045586536.0
Sierra Oncology Inc / SRRA FAQ
Can you describe the business of Sierra Oncology Inc?
Sierra Oncology, Inc. is a clinical stage drug development company of therapeutics for the treatment of cancer. The company is headquartered in Vancouver, British Columbia and currently employs 109 full-time employees. The company went IPO on 2015-07-16. The Company’s lead product candidate, momelotinib, which is a selective and orally bioavailable janus kinase one (JAK1), janus kinase two (JAK2) and activin a receptor type one (ACVR1) inhibitor under investigation for the treatment of myelofibrosis. The firm is also developing a portfolio of deoxyribonucleic acid (DNA) damage response (DDR) assets, consisting of SRA737 and SRA141. SRA737 is a bioavailable small molecule inhibitor of checkpoint kinase 1 (Chk1), which is a key regulator of cell cycle progression and the DDR network. SRA141 is a bioavailable small molecule inhibitor of Cell division cycle 7 kinase (Cdc7).
What is the current price of SRRA stock?
The current stock price of SRRA is 54.99 null. The price increased by 0.04% in the last trading session.
Does Sierra Oncology Inc pay dividends?
SRRA does not pay a dividend.
What is the ChartMill technical and fundamental rating of SRRA stock?
SRRA has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
How is the valuation of Sierra Oncology Inc (SRRA) based on its PE ratio?
Sierra Oncology Inc (SRRA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-6.77).